Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Opus Genetics Inc.

    NASDAQ: IRD · Real-Time Price · USD
    0.93
    -0.01 (-1.20%)
    At close: Jun 17, 2025, 3:59 PM
    0.94
    1.04%
    After-hours: Jun 17, 2025, 05:49 PM EDT

    Opus Genetics Statistics

    Share Statistics

    Opus Genetics has 59.66M shares outstanding. The number of shares has increased by null% in one year.

    Shares Outstanding

    n/a
    		 59.66M

    Shares Change (YoY)

    n/a
    		 n/a

    Shares Change (QoQ)

    n/a
    		 n/a

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 12,973

    FTD / Avg. Volume

    n/a
    		 1.4%

    Short Selling Information

    The latest short interest is 154.73K, so 0.26% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 154.73K

    Short % of Shares Out

    n/a
    		 0.26%

    Short % of Float

    n/a
    		 0.27%

    Short Ratio (days to cover)

    n/a
    		 1.22

    Valuation Ratios

    The PE ratio is -0.55 and the forward PE ratio is -1.77. Opus Genetics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.55

    Forward PE

    n/a
    		 -1.77

    PS Ratio

    n/a
    		 2.89

    Forward PS

    n/a
    		 1.2

    PB Ratio

    n/a
    		 4.73

    P/FCF Ratio

    n/a
    		 -1.24

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Opus Genetics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.24, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 3.24

    Quick Ratio

    n/a
    		 3.24

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $610,666.67

    Profits Per Employee

    n/a
    		 $-3,196,222.22

    Employee Count

    n/a
    		 18

    Asset Turnover

    n/a
    		 0.3

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by null% in the last 52 weeks. The beta is 0.29, so Opus Genetics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.29

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 0.92

    200-Day Moving Average

    n/a
    		 n/a

    Relative Strength Index (RSI)

    n/a
    		 41.26

    Average Volume (20 Days)

    n/a
    		 923,926

    Income Statement

    In the last 12 months, Opus Genetics had revenue of 10.99M and earned -57.53M in profits. Earnings per share was -2.15.

    Revenue

    n/a
    		 10.99M

    Gross Profit

    n/a
    		 10.98M

    Operating Income

    n/a
    		 -62.07M

    Net Income

    n/a
    		 -57.53M

    EBITDA

    n/a
    		 -57.52M

    EBIT

    n/a
    		 -57.53M

    Earnings Per Share (EPS)

    n/a
    		 -2.15
    Full Income Statement

    Balance Sheet

    The company has 30.32M in cash and 0 in debt, giving a net cash position of 30.32M.

    Cash & Cash Equivalents

    n/a
    		 30.32M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -139M

    Total Assets

    n/a
    		 36.86M

    Working Capital

    n/a
    		 25.32M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -25.58M and capital expenditures 0, giving a free cash flow of -25.58M.

    Operating Cash Flow

    n/a
    		 -25.58M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -25.58M

    FCF Per Share

    n/a
    		 -0.96
    Full Cash Flow Statement

    Margins

    Gross margin is 99.91%, with operating and profit margins of -564.72% and -523.4%.

    Gross Margin

    n/a
    		 99.91%

    Operating Margin

    n/a
    		 -564.72%

    Pretax Margin

    n/a
    		 -523.4%

    Profit Margin

    n/a
    		 -523.4%

    EBITDA Margin

    n/a
    		 -523.31%

    EBIT Margin

    n/a
    		 -564.72%

    FCF Margin

    n/a
    		 -232.68%

    Dividends & Yields

    IRD does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for IRD is $6, which is 545.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $6

    Price Target Difference

    n/a
    		 545.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Nov 6, 2020. It was a backward split with a ratio of 1:4.

    Last Split Date

    n/a
    		 Nov 6, 2020

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:4

    Scores

    Altman Z-Score

    n/a
    		 -8.23

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist